Table 2:
Lifetime brain cancer risksa
| Age at Treatment (yr) | Sex | Life Expectancy (mRS Score) | Lifetime Brain Cancer Risk (per 100,000 Individuals) (Mean) (95% CI) |
|---|---|---|---|
| 70 | M | Normal (0–2) | 8.14 (1.52–23.82) |
| 70 | M | Reduced (3–5) | 2.33 (0.44–6.82) |
| 70 | F | Normal (0–2) | 2.47 (0.52–6.84) |
| 70 | F | Reduced (3–5) | 0.66 (0.14–1.83) |
| 50 | M | Normal (0–2) | 27.35 (5.25–80.16)b |
| 50 | M | Reduced (3–5) | 5.26 (1.01–15.40) |
| 50 | F | Normal (0–2) | 7.32 (1.55–20.36) |
| 50 | F | Reduced (3–5) | 1.39 (0.29–3.85) |
a
Risks were calculated using NCI methodology (https://irep.nci.nih.gov/radrat/), adjusted for life expectancy.15 The average dose for a CT+CTA+CTP examination was estimated from published literature.16
b
To assume a conservative approach, we used the highest modeled risk (50-year-old male patient with normal life expectancy) for our base case scenario.